Share on

Global Cell Counting Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product, End User & Region – Industry Forecast (2023 to 2028)

Published: March, 2023
ID: 5763
Pages: 175
Formats: report pdf report excel report power bi report ppt

Cell Counting Market Size (2023 to 2028)

The size of the global cell counting market is estimated to be worth USD 1.26 billion in 2023. This value is forecasted to be growing at a CAGR of 6.87% to reach USD 1.75 billion by 2028.

Cell counting is a counting method for medical applications and plays an essential role in research and clinical activities. The number of cells in liquid media is expressed in cells per unit volume or concentration. Many treatment procedures require cell counts to perform additional procedures. Cell counting is one of the most frequently performed diagnostic and research laboratories in biotechnology, pharmacy, and medicine. Cells can be counted in manual or automatic cell counters. Automated cell counters are designed to solve the problems of manual cell counting.

Cell counters play an essential role in determining the concentration of blood cells, the presence of pathogens, the toxic effect of certain drugs on model cells, and many more. The number of cells is expressed as the number of cells per unit volume in a liquid medium. Various cell count products are instruments, consumables, spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Cell counting is used in multiple applications, such as research institutes, hospitals, diagnostic laboratories, pharmaceutical, biotechnology companies, etc.

MARKET DRIVERS:

The significant factors driving the growth of the global cell counting market are the increasing incidence of cancer and AIDS, corporate and government funding for cell research, and improved IT solutions and better analytical instruments for a picture.

Factors that are increasing the cell counting market emphasize cell counting in the diagnosis and treatment of life-threatening diseases such as cancer and a wide range of cell counting applications. For example, according to the American Cancer Society, nearly 1,688,820 new cancer cases are expected in 2018 in the United States, and approximately 621,840 deaths. Besides, increased "direct" spending and the use of new cell counting technologies have led to the market's growth.

The increasing prevalence of infectious diseases such as sepsis, malaria, influenza, measles, cholera, vector-borne diseases, chikungunya, polio, etc., increases the demand for cell counting methods for diagnosis, which in turn can increase the overall number of cells grown in the device market. According to the World Health Organization (WHO), in 2018, around 241 million people were infected with malaria in approximately 88 countries, and about 442,200 died from malaria. According to the same source, in 2018, the African region had the highest cases, around 99.6% of malaria infection, due to Plasmodium falciparum, followed by the Western Pacific with 72.4% and the Eastern Mediterranean with 68%. Due to Plasmodium vivax, malaria infection was dominant in the North American region, with 72.5% of cases in 2018. Hence, this factor is expected to positively influence the growth of the global cell counting devices market.

MARKET RESTRAINTS:

Some factors hamper the growth of the cell counting market, such as the high cost of cell analysis, the lack of highly skilled professionals, and the lack of adequate research infrastructure, especially in developing and underdeveloped countries.

Impact of COVID-19 on the global cell counting market:

The unprecedented outbreak of covid-19 has affected the different markets in production and manufacturing, and distribution during the first half of 2020. The life sciences markets have been negatively impacted. Biopharmaceutical innovators are leading the human reaction to the covid-19 pandemic. Major pharmaceutical companies are researching the SARS-COV-2 genome and developing a vaccine to combat the disease.

However, the cell counting market had experienced little growth decline during the first quarter of 2020, as the proliferation of Coronavirus has led to the nationwide lockdown. The high impact rendering factor is the increase in the prevalence of chronic diseases that require next-generation therapeutics; this upsurge has resulted in intensive research efforts that necessitate specialized cell counting instruments.  The counting instruments supply chain had been disrupted due to the ban on transportation.  The cell counting activities had partially been disrupted owing to the stringent government guidelines. However, significant biopharmaceutical companies and medical institutes have been working toward identifying the virus genome and how it affects the human body. Few tests have shown that some patients with COVID-19 have higher white blood cell and neutrophil levels and lower lymphocyte production. According to other research, the neutrophil-to-lymphocyte ratio can be used as a biomarker to predict the outcome of an infection.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2022 to 2028

Base Year

2022

Forecast Period

2023 to 2028

Segments Covered

By Product, Consumables, End User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

This research report on the global cell counting market has been segmented and sub-segmented based on the product, consumables, end-user, and region.

Cell Counting Market - By Product:

  • Instruments
  • Cell Counters
  • Hematology Analysers
  • Spectrophotometer
  • Flow Cytometer
  • Hemocytometer
  • Others

The spectrophotometers segment accounted for the market's largest share based on the product due to the enhanced data visualization and analysis software.

Cell Counting Market – By Consumables:

  • Microplates
  • Reagent
  • Assay Kits

Cell Counting Market – By End User:

  • Pharmaceutical & Biotechnology Industries
  • Hospitals & Diagnostic Laboratories
  • Research & Academic Institutes

Cell Counting Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, North America accounted for the largest share in 2019 due to the rise in the aging population, high investments by the government in the healthcare sector, and large companies in this area.

North America is anticipated to dominate the overall cell counting market during the forecast period. The central part is mainly due to a larger group of patients and the increase in the geriatric population. In the North American region, the United States holds the largest market share due to the growing number of chronic diseases and an increasing number of research and development programs. According to the latest estimates from the Centers for Disease Control and Prevention, 38,741 people were diagnosed with HIV in the United States in 2019. According to statistics, many patients and the high disposable income have driven market growth in the region.

South America is the second-largest market for cell counting, with growth driven by improved diagnostic and treatment methods that support growing demand in this market. Improved technology in the manufacture of cell counting instruments further enhances the development of this market.

The Asia Pacific is the fastest-growing cell counting market due to continuously developing economies such as India and China and a huge patient population. Supportive government policies, such as reducing excise and customs duties followed by exemptions from the service tax, will stimulate market growth. Also, the increase in healthcare spending is boosting the market in the region. 

Japan accounts for the largest market share in the Asia-Pacific cell counting market in 2017. Market growth is attributed to the development of medical devices in addition to research and development activities. Besides, the major market players are involved in exporting medical devices by targeting developing markets to gain a reasonable market share.

India is considered to be the fastest-growing market for medical equipment manufacturers. In India, the cell count market is growing due to cheap raw materials, better access to labor, and an increasing number of hospitals and healthcare facilities. India is one of the top destinations for medical tourism, especially for orthopedic surgeries, which further influences the market's growth.

KEY MARKET PARTICIPANTS:

Companies dominating the global cell counting market profiled in the report are Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, Bio-Rad Laboratories, Merck Millipore, Inc., GE Healthcare, Becton, Dickinson and Company, and PerkinElmer, Inc.

RECENT MARKET DEVELOPMENTS:

  • Danaher (US) acquired GE Life Sciences' Biopharma company, GE Healthcare, in 2020. With Danaher's Life Science division, this corporation will be developed as a stand-alone operating entity. Danaher is a leading research and technology innovator dedicated to assisting clients in overcoming challenging problems and enhancing the global quality of life. Its world-class brands hold leading roles in the competitive and exciting health care, environmental, and applied end-markets.
  • Agilent Technologies purchased BioTek Instruments, Inc. in 2019. (US). Agilent Technologies' presence in the cell counting industry will be strengthened as a result of this acquisition. BioTek is a world leader in the growth, manufacturing, and delivery of cutting-edge life science instruments. Cell imaging devices, microplate readers, washers, dispensers, automatic incubators, and stackers are among the company's several items. BioTek is a good strategic match for Agilent, "Agilent's president and CEO, Mike McMullen, said as much. "Our multi-year growth plan to extend our presence in cell analysis will be accelerated by the merger of these two firms.
  • Perkin Elmer and Accenture signed an agreement in 2019 to join Accenture's Open Partner Ecosystem Program, aiming to help researchers speed up drug development and increase patient outcomes.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample